Search clinical trials for: Discontinuation of CDK4/6 inhibitor Palbociclib

Total 1207 results

Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Breast Cancer

Germany
Sidney Kimmel Comprehensive Cancer Center at Johns...
Safeway Foundation

Recruiting

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

Breast Cancer

United States
RenJi Hospital

Recruiting

CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer

Breast Cancer

China
Henan Cancer Hospital

Recruiting

A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors

Digestive System Tumors

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Recruiting

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
Royal Marsden NHS Foundation Trust
Pfizer; Hoffmann-La Roche

Recruiting

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression (FAIM)

Advanced Breast Cancer | Metastatic Breast Cancer | ER+ Breast Cancer

United Kingdom
Lebanese University
Haykel Hospital

Recruiting

Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA (PTST_PALBEVA)

Cancer | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Chemotherapy | Solid Tumor | Immunotherapy | Targeted Therapy | Precision Therapy

Lebanon
Hunan Cancer Hospital

Not yet recruiting

Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.

Breast Cancer | Endocrine Therapy | CDK4/6 Inhibitors | Subsequent Treatment
Pfizer

Active, not recruiting

PF-07104091 as a Single Agent and in Combination Therapy

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer

United States, China, Japan, Mexico, Bulgaria, Argentina
Erasmus Medical Center

Active, not recruiting

Evaluating the Incidence of Pseudo-Acute Kidney Injuries in Patients With Metastatic Breast Cancer on CDK4/6 Inhibitors Trough Cystatin C Analysis (CYSTATINcDK4/6)

Advanced Breast Cancer

Netherlands
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Early Breast Cancer

China
Taixing People's Hospital

Recruiting

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

NSCLC

China
G1 Therapeutics, Inc.

Completed

Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1

Healthy Volunteers

Netherlands
G1 Therapeutics, Inc.

Completed

First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Volunteers

Healthy Volunteers

Netherlands
G1 Therapeutics, Inc.

Recruiting

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Extensive-stage Small-cell Lung Cancer

Spain, Greece, Turkey, Poland, Georgia, Austria, Belgium, Bulgaria, Germany, Hungary
Sudipto Mukherjee

Active, not recruiting

Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | AML

United States
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Advanced HR+ HER2 Negative Breast Carcinoma
Istituto Scientifico Romagnolo per lo Studio e...
Agenzia Italiana del Farmaco

Unknown

CDK4/6-inhibitor or Chemotherapy, in Combination With ENDOcrine Therapy, for Advanced Breast Cancer / KENDO (KENDO)

Metastatic Breast Cancer | Hormone Receptor Positive Breast Cancer | Hormone Receptor Negative Breast Cancer

Italy
Fudan University

Recruiting

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer (BCTOP-L-M01)

Breast Cancer | Advanced Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RADIOCOM)

Chemotherapeutic Toxicity | Radiotherapy; Complications | PARP Inhibitor | Immune Checkpoint Inhibitor | Trastuzumab | Breast Cancer, Familial Male | CDK4/6 Inhibitor | Pertuzumab

China
Borstkanker Onderzoek Groep

Active, not recruiting

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Breast Neoplasm Female

Netherlands
Assistance Publique - Hôpitaux de Paris

Completed

Impact of Renin-Angiotensin System Inhibitors Continuation on Outcome After Major Surgery (STOPORNOT)

Surgery | Renin Angiotensin System

France
Region Örebro County
Helsinki University Central Hospital; Hospital Clinic of Barcelona; University... and other collaborators

Recruiting

Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients (IMPORTANT)

Quality of Life | Advanced Breast Cancer | Metastatic Breast Cancer | Toxicity | Older Patients

Sweden, Finland, Greece, Italy, Norway, Spain
Yongsheng Wang
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Locally Advanced Breast Cancer | Hormone Receptor Positive，HER2-negative Breast Cancer

China
G1 Therapeutics, Inc.

Terminated

Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy

Small Cell Lung Cancer

United States, Croatia, Belgium, Slovakia, Bosnia and Herzegovina, North Macedonia, Serbia, Slovenia
Pfizer

Completed

A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects

Healthy

United States
Pfizer

Completed

European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies (EUCHARIS)

Metastatic Breast Cancer

Spain, Belgium, Sweden, United Kingdom, Austria, Germany, Switzerland
Pfizer

Completed

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

Healthy

United States
Mridula George, MD

Recruiting

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Breast Cancer

United States
Pfizer

Completed

Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption

Healthy

United States
Megalabs

Not yet recruiting

Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg

Bioequivalence
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

China
Pfizer

Completed

Relative Bioavailability For Palbociclib Formulations

Healthy

United States
Memorial Sloan Kettering Cancer Center
Pfizer

Completed

PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

Sarcoma | Liposarcoma

United States
Pfizer

Completed

A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract

Healthy

United States
Pfizer

Active, not recruiting

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Metastatic Breast Cancer

United States
Pfizer

Completed

A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

Healthy, Hepatic Insufficiency

United States
Pfizer

Completed

Study Of Palbociclib (PD-0332991) In Renal Impairment

Renal Impairment

United States
Pfizer

Completed

A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product

Healthy

United States
Pfizer

Completed

Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

Metastatic Breast Cancer

United States
Pfizer

Recruiting

Swedish Ibrance Registries Insights (SIRI) (SIRI)

Malignant Neoplasm of Breast

Sweden
Pfizer

Completed

A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

Metastatic Breast Cancer

Israel
InventisBio Co., Ltd

Completed

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Breast Cancer

United States, China
Pfizer

Completed

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

Healthy

United States
University of Nebraska

Recruiting

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

Breast Cancer

United States
Pfizer

Recruiting

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting. (PERFORM)

Breast Neoplasms

Austria, Germany
Royal Marsden NHS Foundation Trust
Pfizer; Roche Pharma AG; Institute of Cancer Research, United Kingdom

Unknown

PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib (PIPA)

Breast Cancer | Advanced Solid Tumours

United Kingdom
Razelle Kurzrock, MD

Withdrawn

Histology-Independent Study of Palbociclib in Patients With Advanced Cancer

Cancer, Advanced

United States
Pfizer

Completed

Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions

Healthy

United States
Pfizer

Completed

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Metastatic Breast Cancer

United States

3

Subscribe